Smith Group Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Smith Group Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-28,840	Closed	-$1.77M	–	418
2014 Q3	$1.77M	Sell	28,840 -60	-0.2%	-$2.59K	0.07%	160
2014 Q2	$1.32M	Buy	+28,900	New	+$1.18M	0.05%	171

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

TRV

Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CGT

Capital Guardian Trust Los Angeles, California $7.42B AUM 13.6% 1-Year Est. Return

Smith Group Asset Management's AGIO Position: Q4 2014 in Review

Smith Group Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2014, closing a stake of 28,840 shares — an estimated $1.77M sold.

Smith Group Asset Management first reported a position in AGIO in Q2 2014 and held it in 2 quarters. The position peaked at $1.77M in Q3 2014. 142 funds tracked by Wall St. Rank hold AGIO as of Q4 2014.

Smith Group Asset Management reported no remaining Agios Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Smith Group Asset Management sold 28,840 Agios Pharmaceuticals shares in Q4 2014, an estimated $1.77M.
Smith Group Asset Management first reported a position in Agios Pharmaceuticals in Q2 2014 and held it in 2 quarters.
Smith Group Asset Management's Agios Pharmaceuticals position peaked at $1.77M in Q3 2014.
142 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2014.

Based on Smith Group Asset Management's 13F filing for Q4 2014, filed 27 Jan 2015.